腹腔内注射白细胞介素-2免疫疗法治疗复发性卵巢癌后的长期生存
Prolonged survival after intraperitoneal interleukin-2 immunotherapy for recurrent ovarian cancer.
作者信息
Minor David R, Moores Samantha P, Chan John K
机构信息
California Pacific Medical Center Research Institute, 2200 Webster St. Suite 511, San Francisco, CA 94115, United States.
California Pacific Medical Center Research Institute, 2200 Webster St., San Francisco, CA 94115, United States.
出版信息
Gynecol Oncol Rep. 2017 Sep 25;22:43-44. doi: 10.1016/j.gore.2017.09.009. eCollection 2017 Nov.
Abstract
•A case report of a 14 year remission of recurrent ovarian cancer with intraperitoneal aldesleukin (IL-2) is presented.•Intraperitoneal IL-2 was given with little toxicity.•Immunotherapy may have the potential for durable remissions in ovarian cancer.
摘要
• 本文报告了一例复发性卵巢癌患者经腹腔注射白细胞介素-2（IL-2）后缓解14年的病例。
• 腹腔注射IL-2的毒性很小。
• 免疫疗法可能对卵巢癌有持久缓解的潜力。
Zotero 插件